We previously showed that exogenous testosterone (T) inhibited GnRH-antagonist-stimulated spermatogenic recovery in irradiated rats through an androgen-receptor-mediated action. In the present study, we tested whether the inhibition is attributable to T, a specific androgenic metabolite of T, or a general property of androgens in this system. In addition, we also tested whether estradiol-17␤ (⌭2), a metabolite of T, is similarly inhibitory. Rats irradiated with 5 Gy were treated with a GnRH antagonist during wk 3-7. Neither irradiation nor GnRH-antagonist treatment produced biologically significant changes in the relative intratesticular levels of several androgenic metabolites. Next, groups of rats, irradiated and treated with GnRH antagonist as above, were given various doses of one of the following androgens: T, 5␣؊dihydrotest-osterone, 7␣؊methyl-19-nortestosterone, methyltrienolone, or E2. The percentage of tubules showing differentiation (tubule differentiation index) was increased to 68% by the GnRH antagonist, from a value of 0.1% in irradiated-only rats at 13 wk after irradiation. All of the added androgens inhibited spermatogenic recovery, lowering the tubule differentiation index to between 0.4 -36%, but no inhibition was observed with the addition of E2. Of all the androgen treatments tested, T (given as daily injections of T propionate) minimally inhibited spermatogenic recovery while maintaining androgen-responsive tissue weights, and might be most useful in clinical studies. Hormonal measurements in androgen-treated rats were most consistent with the androgen inhibition of spermatogenic recovery in irradiated rats being a combined result of a direct inhibitory effect of all androgens on the testis and an indirect effect through the pituitary by raising levels of FSH, which seems to add to the inhibition of spermatogenic recovery. (1), Wistar rats (2), rhesus monkeys (3), and presumably also in humans (4), low doses of 1-5 Gy radiation produced prolonged depression of spermatogenesis by disrupting the differentiation of surviving spermatogonia. Consequently, undifferentiated A spermatogonia were the only germ cells present in these irradiated testes for an extended period of time. Treatment of irradiated LBNF 1 rats with GnRH analogs during this postirradiation period stimulated spermatogonial differentiation, resulting in spermatogenic recovery (5, 6) . Subsequently, we demonstrated that exogenous testosterone (T), acting through the androgen receptor (AR), suppressed this GnRH-analog-stimulated spermatogenic recovery (7). That study showed that precursors of T and byproducts formed during generation of T were not necessarily involved in the inhibition; it did not rule out the possibilities that other androgenic or estrogenic metabolites of T or extratesticular targets were involved.
I
N LBNF 1 (F 1 hybrids of Lewis and Brown-Norway) rats
(1), Wistar rats (2), rhesus monkeys (3), and presumably also in humans (4) , low doses of 1-5 Gy radiation produced prolonged depression of spermatogenesis by disrupting the differentiation of surviving spermatogonia. Consequently, undifferentiated A spermatogonia were the only germ cells present in these irradiated testes for an extended period of time. Treatment of irradiated LBNF 1 rats with GnRH analogs during this postirradiation period stimulated spermatogonial differentiation, resulting in spermatogenic recovery (5, 6) . Subsequently, we demonstrated that exogenous testosterone (T), acting through the androgen receptor (AR), suppressed this GnRH-analog-stimulated spermatogenic recovery (7) . That study showed that precursors of T and byproducts formed during generation of T were not necessarily involved in the inhibition; it did not rule out the possibilities that other androgenic or estrogenic metabolites of T or extratesticular targets were involved.
Because an inhibitory effect of T on spermatogonial differentiation was contrary to the usual action of this hormone in the testis, we believe that it was essential to determine whether this unusual effect was indeed caused by T, a specific metabolite of T, or a general property of androgens in this system. There is extensive evidence on estrogens (and now, some accumulating evidence on androgens) that different ligands for the receptor can induce different responses. For example, there is differential transactivation by T and 5␣-dihydrotestosterone (DHT) of genes with different androgen response element sequences (8) . Although T is considered to be the major androgen regulating normal spermatogenesis because of its high intratesticular concentration, it is possible that a particular metabolite of T regulates spermatogonial differentiation in the irradiated rats.
One of the ways to reconcile the inhibitory effect of T with previous dogma would be if irradiation altered androgen metabolism, resulting in disproportionate changes, which could be reversed by GnRH-antagonist treatment, in the testicular levels of this particular metabolite. Therefore, in the present study, we correlated the intratesticular levels of several metabolites of T in testes of unirradiated, irradiated, and irradiated hormone-treated rats with the ability of the spermatogonia to differentiate.
A second way to explain the inhibitory action of T, irrespective of any alteration in steroid metabolism, is that irradiation could induce a change in AR coactivators or corepressors, such that now T and/or one or more of its metabolites act in an inhibitory (rather than a stimulatory) mode. For example, specific AR coactivators can confer androgenic activity to estradiol-17␤ (⌭2) or hydroxyflutamide (9) . Hence, it is possible that, in the irradiated testis, inhibitory activity could be conferred on only a subset of the metabolites of T. To directly test this possibility, we measured the spermatogenic inhibitory action after irradiation of different androgens and E2 by providing them exogenously.
We tested E2, which is formed from T by aromatase. Under normal conditions, E2 does not act via AR, but there are estrogen receptors in the testis; and, with certain coactivators (9) , E2 can act via the AR. The androgens tested, in addition to T, were DHT (a 5␣-reduced metabolite of T), 7␣Ϫmethyl-19-nortestosterone (MENT, a non-5␣-reducible, but aromatizable, androgen), and methyltrienolone (R1881, a nonmetabolizable androgen) (Fig. 1) . DHT is regarded as a more potent androgen than T because it has a higher affinity for AR (10) and can stimulate and maintain spermatogenesis more efficiently than T (11) (12) (13) . MENT, a synthetic 19-norandrogen derivative, cannot be 5␣-reduced (14) ; and hence, in contrast to T, its biological activity is not differentially amplified in male accessory sex organs, compared with the testis (15) , which has less 5␣-reductase activity. MENT is known to have an increased affinity for AR and enhanced nuclear retention, compared with T (16). R1881 is a nonmetabolizable synthetic androgen, which also binds to AR with greater affinity than T (17) but has very little affinity for androgen-binding protein (18, 19) . Because R1881 is not 5␣-reduced, it shows weaker effects, compared with T, on the accessory sex organs at doses that produce equivalent stimulatory effects on the testis (20) .
Testing the different androgens would have significant clinical relevance if it enabled us to determine whether any specific androgen preserved peripheral androgenicity with minimal inhibition of spermatogonial differentiation. If such a selective AR modulator (21) existed or could be developed, it might prove useful in hormone treatment strategies in humans rendered azoospermic by radiation or chemotherapy, with the aim of restoring their fertility while minimizing the loss of muscle mass and libido resulting from GnRHanalog treatment.
Materials and Methods Materials
Cetrorelix was provided by Dr. Thomas Reissmann (ASTA Medica, Frankfurt, Germany). T, E2, DHT, T propionate (TP), molecusol (2-hydroxy-propyl-␤ cyclodextrin), and dextran-coated charcoal were obtained from Sigma (St. Louis, MO). MENT was purchased from Steraloids (Wilton, NH). Methyltrienolone (R1881) was a gift from Dr. Jan T. M. Vreeburg (Erasmus University, Rotterdam, The Netherlands). Alzet osmotic pumps were obtained from Alza Corp. (now Diuret) (Palo Alto, CA). SILASTIC brand tubing (catalog no. 602-305) was purchased from Dow Corning Corp. (Midland, MI). The antibodies used in the FSH assay were a monoclonal antibody against recombinant human FSH␤ (FSH 56A) and a polyclonal antibody against recombinant human FSH␣ (R93-2705), both donated by Organon (Oss, The Netherlands). T-antiserum-coated tubes were obtained from Diagnostic Systems Laboratories, Inc. (Webster, TX).
Adult LBNF 1 male rats were obtained from Harlan Sprague Dawley, Inc. (Indianapolis, IN) and housed in animal facilities approved by the American Association for Accreditation of Laboratory Animal Care, in accordance with current regulations and standards of The United States Department of Agriculture and the Department of Health and Human Services, NIH. They were maintained on a 12-h light, 12-h dark cycle and were allowed food and water ad libitum. All rats were acclimatized for at least 10 d before the initiation of experiments, at which time they were 9 -12 wk of age.
Irradiation
Rats were anesthetized with an im injection of 0.72 mg ketamine/kg body weight and 0.22 mg acepromazine/kg body weight. The rats were placed on their backs, and 5 mm of tissue-equivalent bolus material (Superflab; Mick Radio-Nuclear Instruments Inc., Bronx, NY) was placed over the scrotum to provide a build-up layer. The lower part of FIG. 1. Schematic pathway of steroid metabolism, showing T metabolites and other androgens analyzed in the present study (bold font), their chemical structure differences, and enzymes involved in their interconversion. MENT and methyltrienolone are the two synthetic androgens tested, which are non-5␣-reducible and nonmetabolizable, respectively. HSD, Hydroxysteroid dehydrogenase. the body, with the anterior edge of the irradiation field positioned about 6 cm above the base of the scrotum, was irradiated using a 60 Co ␥-ray unit (Eldorado 8; Atomic Energy of Canada Ltd., Ottawa, Ontario, Canada). A single dose of 5 Gy was administered at a dose rate of 0.96 Gy/min. Control animals underwent anesthesia and sham irradiation.
Hormone treatment
At 3 wk after irradiation, the rats were treated with a GnRH antagonist, Cetrorelix, as described earlier (7) . Cetrorelix acetate was used at a dose of 1.5 mg/kg to bring about an immediate effect, and a dose of Cetrorelix pamoate of 1.5 mg/kg was given to have a prolonged effect. This treatment was shown, in irradiated rats, to depress LH, FSH, and intratesticular T (ITT) levels within a day; suppression was maintained for approximately 3-4 wk and reached a maximum at 2 wk (7, 22) .
The spermatogenic and/or androgenic effects of DHT, MENT, R1881, or E2 (relative to T) were tested as outlined in Fig. 2 . The unirradiated, irradiated-only, and GnRH-antagonist-only-treated irradiated groups each consisted of a minimum of 10 rats. Each treatment group that received one of the androgens or E2 in addition to the GnRH antagonist consisted of 4 or 5 rats. Three weeks after irradiation, groups of rats irradiated with 5 Gy received sc injections of Cetrorelix. Some groups of these treated rats also received an androgen in two doses, differing by a factor of 3, or comparable doses of T starting at 3 wk after irradiation and continuing for a period of 4 wk. In each case, the other androgen was delivered in a mode as previously published (see below), and T was given in the same manner. Two groups of these GnRH-antagonisttreated irradiated rats also received E2 or T delivered in a comparable manner.
In the first comparison, SILASTIC capsules, of two different lengths, containing T (2 cm and 6 cm) or DHT (5 cm and 15 cm) were implanted sc after preequilibriation in a 1% BSA solution. The doses were selected based on the relative doses of T and DHT required for the maintenance of testicular function and accessory organ weights in rats (11) . The release rates of T and DHT from the capsules have been reported to be about 30 and 25 g/cm⅐d, respectively (23, 24) . In the second comparison, miniosmotic pumps (model 2004) were implanted sc, to administer two different doses of T (60 g and 180 g/d) or of MENT (10 g and 30 g/d) over a period of 4 wk. The steroids were suspended in 45% aqueous solution (wt/vol) of molecusol (15) . The doses of these two androgens were selected in accordance with their relative average androgenic potencies toward a variety of tissues (25) . In the third comparison, two different amounts of TP (100 g and 300 g/d) or of R1881 (300 g and 900 g/d) were administered as daily sc injections in corn oil. The doses and delivery method were chosen based on those used earlier in rats for the maintenance of the weights of the testes and other androgen-responsive tissues (20) . In the fourth comparison, SILASTIC capsules containing E2 (0.5 cm) and T (6 cm) were implanted sc. This dose of E2 was shown to have effects on spermatogenesis (26) and produce a greater elevation of serum E2 levels than the dose of T used (27) . Lower doses of E2 were not tested because, as will be shown in Results, no inhibition of spermatogenic recovery was observed with 0.5-cm E2.
Some rats were killed at 5 wk after irradiation, after 2 wk of hormone treatment, which is the midpoint of the treatment of the other rats, for hormone measurements. In the other rats, the treatment was continued for up to 7 wk after irradiation, at which time the implants were removed or the injections were stopped, and the rats were killed at 13 wk after irradiation to measure spermatogenic recovery.
Hormone and androgen response measurements
At the time the rats were killed, blood was collected by cardiac puncture, under ketamine-acepromazine anesthesia. The serum was separated and stored at -80 C. In all rats, the right testis was freed of the tunica, weighed, collected on ice, and homogenized in a known amount of cold water. In some cases, an aliquot was removed and the sperm heads counted; the remainder of all samples was stored at -80 C for ITT analysis. In addition, in androgen-treated rats, three androgen-responsive tissues (the seminal vesicle with its fluid, ventral prostate, and the bulbocavernosus muscle) were also removed, cleared of extraneous material, and weighed.
Serum levels of FSH and LH were measured using immunofluorometric assays (Delfia; Wallac, Inc. OY, Turku, Finland) as previously described (28, 29) . The minimum levels of detection of LH and FSH by this method are 0.04 ng/ml and 0.1 ng/ml, respectively.
ITT was assayed, in samples from experiments involving exogenous steroid hormone treatment, by using T-antiserum-coated tubes. The assay was done directly in the testicular homogenates, which were not centrifuged, using T standards prepared in 0.1% gelatin in PBS (7). ITT was expressed as the amount per gram testis, to reflect the actual concentration of T to which the testicular cells are exposed. In the normal testis, in which the concentration of T is much higher than the concentration of AR (30), the T concentration determines the occupancy of the AR, which should be nearly 100% because the dissociation constant is low (31) . The amount of AR in irradiated rats has not been quantified, but immunohistochemistry indicates that, in the AR-positive somatic cells, the average levels are similar to unirradiated rats (32) . Although the decrease in testicular volume results in a higher concentration of AR, the concentration of T also increases and still seems to be much higher than that of the AR. However, in the irradiated rats treated with GnRH antagonists, it is possible [depending on the effects of T deprivation on the AR levels in testis, which are still not clear (30) ] that the concentration of T is less than that of AR. In this case, provided the amount of AR per AR-positive somatic cell remains constant, that the receptor occupancy will be determined by the total amount of T per testis, because the number of AR-positive cells per testis remains unchanged. Hence, we will also express ITT as the amount per testis.
The cross-reactivities of DHT, R1881, and TP in the T assay were 6.5%, 0.9%, and 0.08%, respectively. Because MENT treatment did not elevate the measured ITT concentrations, its cross-reactivity in the T assay should be minimal.
In addition, studies were performed to determine the content of androgenic metabolites, along with that of T, in the testes of a subset of the hormone-treated irradiated rats, to test whether the spermatogenic inhibition was caused by altered androgen metabolism along the pathways shown in Fig. 1 . Of the rats used for this purpose, the unirradiated, irradiated-only, and irradiated GnRH-antagonist-treated rats, with and without T, were selected from a different experiment (n ϭ 4 in each group), and the GnRH-antagonistϩDHT-treated irradiated rats were those in comparison 2.
Serum T and DHT were analyzed, in these samples, by RIA without extraction, as previously described (33), with the following modification. Before measurement of DHT, T was oxidized using a commercial kit (Biotrak T/DHT-[ 3 H]; Amersham Pharmacia Biotech, Piscataway, NJ) to avoid cross-reaction with the antibody. The interassay coefficients of variation of the RIAs for each steroid were all less than 15%. The values obtained from the measurements of androgen-free serum, prepared by stripping serum from androgen-suppressed male rats with charcoal, were subtracted from the RIA measurements of the experimental samples, to produce the corrected steroid concentrations.
Before the RIA of testicular homogenates for androgenic metabolites and T, 1000 cpm tritiated T, androsterone, androstenedione, androstanediol, or DHT were added to aliquots of the homogenates. The homogenates were then extracted two times with ether and dried under nitrogen gas. The dried extracts were resuspended in water. A portion of the extracted samples was removed for scintillation counting, and the FIG. 2. Schematic of the experimental protocol. GnRH antagonist (Cetrorelix) was injected at 3 wk after irradiation. Steroid hormones were given from wk 3-7 after irradiation.
counts were used to calculate the recovery of each steroid from the ether extractions. The remaining portion was defatted by elution through a C18 column (Bond Elut, catalog no. 1210-2028; Varian, Harbor City, CA) using methanol. The eluate was then dried under nitrogen. The defatted extracts were resuspended in Tris-buffered saline with 0.1% gelatin. A portion of the resuspended sample was removed for scintillation counting to correct for recovery from the elution step. The remaining portion of the sample was then assayed for T, androsterone, androstenedione, androstanediol, and DHT as previously described (33) . Measurements from charcoal-stripped samples of testicular homogenate were subtracted to produce the final steroid concentrations. The amounts of all these androgens in testis were expressed both per gram testis and per testis.
Evaluation of spermatogenesis
Spermatogenesis was evaluated in rats killed at wk 13 after irradiation. An aliquot from the right testicular homogenate was sonicated at 4 C for 4 min, as described earlier (34) . The sonication-resistant sperm heads, representing nuclei of 12-19 spermatids, were counted in a hemocytometer.
For histological analysis, the left testis was fixed in Bouin's fluid and embedded in paraffin or plastic (JB4; Polysciences, Warrington, PA), and 4-m sections were cut and stained with hematoxylin. To evaluate spermatogenesis after hormone treatment, 200 seminiferous tubules in one section from each animal were scored for the most advanced germcell stage present in each tubule. A tubule was scored as differentiating if it contained 3 or more cells that had reached the type B spermatogonia stage or later (34) . The tubule differentiation index (TDI), which is the percentage of tubules showing differentiation, was then computed.
Statistical analysis
For sperm counts, LH, serum androgen, and intratesticular steroid measurements (the averages and sem) were calculated on log-transformed data. The organ weights, TDI, and FSH were represented as arithmetic mean Ϯ sem. The differences between the treatment groups were analyzed first by one-way ANOVA. If the difference was significant (P Ͻ 0.05), a Dunnett's test was performed to determine the significance of the difference between the treated groups and a selected control group (irradiated-only or irradiated-and-treated-with-GnRHantagonist-alone). To compare the difference among specific groups in GnRH-antagonistϩsteroid-hormone-treated irradiated rats, a Student's t test was performed. A computer-assisted statistics program (SPSS, Inc., Chicago, IL) was used for all analyses.
Results

Effects of irradiation and hormone treatments on androgen metabolite levels
We addressed the possibility of alterations in the androgen metabolism after irradiation or hormone treatments, by analyzing the concentrations and amounts of various androgenic metabolites in the testis and serum of unirradiated rats, irradiated-only rats, and GnRH-antagonist-treated irradiated rats, with or without T or DHT. In irradiated rats, the testicular concentrations of endogenous androstenedione, DHT, androstanediol, and androsterone did not show significant changes from values in the unirradiated rats, whereas ITT showed a 2.8-fold increase in this experiment (Fig. 3, A-E) . Thus, spermatogenic inhibition cannot be attributed specifically to either the absence or inhibitory action of any one of these androgenic metabolites. The fact that spermatogenic inhibition was associated with greater elevations of ITT, compared with other androgenic metabolites tested, implies that none of these androgens can be more inhibitory than T.
GnRH-antagonist treatment suppressed the intratesticular levels of all of the androgens tested in the irradiated rats. Androstenedione, T, and androstanediol concentrations were significantly suppressed to 48%, 10%, and 61%, respectively, of the irradiated-only concentrations, whereas the suppression of DHT (78%) and androsterone (60%) were not significant (Fig. 3, A-E) . Thus, the stimulation of recovery of spermatogonial differentiation produced by GnRH-antagonist treatment cannot be attributed to a requirement for any of these androgens. Because T was the most effectively suppressed androgen by the GnRH antagonist, T must, if androgens are inhibitory, be the most inhibitory of all the androgens tested, at least based on changes in their endogenous levels.
We next examined the intratesticular levels of androgens in GnRH-antagonist-treated irradiated rats given additional treatment with T, which suppresses recovery of spermatogenesis. The addition of 6 cm T slightly increased the intratesticular concentrations of T in GnRH-antagonist-treated irradiated rats (Fig. 3G) . Although the increase was not significant in this experiment, significant increases were observed in other experiments. The amounts of ITT per testis were increased with both lengths of T implants, with the increase being significant after the 6-cm implant (Fig. 4G) . In contrast, intratesticular concentrations of androstenedione, DHT, androstanediol, and androsterone were generally suppressed after the addition of T to GnRH antagonist (Fig. 3, F and H-J), but their amounts per testis were generally unchanged (Fig. 4, F and H-J) . These results further support our hypothesis that T itself, and not an androgenic metabolite, is the major factor inhibiting recovery of spermatogenesis under these conditions.
Effects of various steroid treatments on spermatogonial differentiation
Irradiation with 5 Gy almost completely prevented the differentiation of the surviving spermatogenic stem cells, the TDI being 0.1% at wk 13 ( Fig. 5A ) and sperm head count being close to the limit of detection by our counting method (Table 1) . Treatment with the GnRH antagonist, after irradiation, restored the ability of the testis to support stem cell differentiation, raising the TDI, at 13 wk post irradiation, to 68%. The continued progression of reinitiated spermatogenesis, even after discontinuing the treatment, was exemplified by a 1000-fold increase in the sperm head counts in these GnRH-antagonist-treated irradiated rats, compared with irradiated-only rats.
To determine whether 5␣-reduced metabolites of T were capable of inhibiting spermatogonial differentiation, we compared the effects of DHT (relative to T) on GnRH-antagonist-stimulated spermatogonial recovery. Addition of T in 2-cm and 6-cm SILASTIC capsules suppressed the GnRHantagonist-induced tubule differentiation by 90% and 95%, respectively (Fig. 5B) . DHT in 5-cm and 15-cm SILASTIC capsules similarly suppressed the GnRH-antagonist-stimulated tubule differentiation by 93% and 95%, respectively. The sperm head counts in these rats were not different from those in the irradiated-only rats (Table 1) . Because DHT cannot be converted back to T, 5␣-reduced androgens and/or their metabolites can inhibit spermatogonial differentiation in the irradiated rat.
Because it was possible that the inhibitory effect of T was only through conversion to 5␣-reduced forms, we next determined whether MENT, a non-5␣-reducible but aromatizable 19-nortestosterone, also inhibited spermatogonial differentiation after irradiation. Continuous delivery of T in osmotic pumps, at doses of 60 g and 180 g/d, reduced the GnRH-antagonist-stimulated tubule differentiation by 89% and 93%, respectively (Fig. 5C) . A similar mode of treatment with MENT, at doses of 10 g and 30 g/d, more severely suppressed the GnRH-antagonist-stimulated TDI by at least 99% and suppressed sperm head counts to undetectable levels (Table 1) .
After observing that both DHT and MENT treatments inhibited spermatogenic recovery after irradiation, we wanted to rule out the possibility the inhibitors were not these androgens but rather their metabolites. To this end, we tested a nonmetabolizable androgen, R1881. For comparison, T was given in the form of daily injections of TP. Supplementation with 100 g and 300 g TP/d dose-dependently suppressed the GnRH-antagonist-induced differentiation of tubules only by 47% and 57%, respectively (Fig. 5D) . However, R1881 was more effective in suppressing spermatogenic recovery, given that daily injections of 300 g and 900 g R1881 suppressed the GnRH-antagonist-stimulated tubule differentiation by 78% and 94%, respectively. Concurrent with the reduced tubule differentiation, the sperm head counts were also dose-dependently reduced when these two androgens were used in addition to the GnRH-antagonist treatment, but the reduction produced by a lower dose of TP was less than that observed with the comparable dose of R1881 (Table 1) .
Inhibition of spermatogenic recovery after irradiation by T and MENT, which are aromatizable, led us to test the effect of E2 on such recovery. Though a 6-cm T capsule inhibited the GnRH-antagonist-stimulated TDI by 95%, as observed earlier, E2 in a 0.5-cm capsule did not significantly alter the
FIG. 3. Intratesticular androstenedione (A and F), T (B and G), DHT (C and H), androstanediol (D and I)
, and androsterone (E and J) concentrations in unirradiated control rats, irradiatedonly rats, and irradiated (5 Gy) rats treated with GnRH antagonist with or without T (2 cm and 6 cm) or DHT (5 cm and 15 cm) in SILASTIC capsules. GnRH antagonist and androgen treatments were started at wk 3 after irradiation and maintained until the rats were killed at wk 5 (n ϭ 4 per group). Significance of the difference (Dunnett's test) from irradiated-only rats (for unirradiated rats and irradiated rats receiving GnRH antagonist and GnRH-antagonistϩandrogen treatments): *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; or from GnRH-antagonist-alonetreated rats (for rats receiving additional hormone treatments): †, P Ͻ 0.5; † †, P Ͻ 0.01; † † †, P Ͻ 0.001.
GnRH-antagonist-induced spermatogenic recovery, as observed by the TDI (Fig. 5E ) and sperm head counts (Table 1) .
Hormone levels during GnRH-antagonist and androgen treatment
Five weeks after irradiation, serum FSH levels were significantly elevated, but LH levels were not altered (Fig. 5, F and K). Although the increase in ITT concentrations at 5 wk after irradiation was not significant in these rats (Fig. 5P) , irradiation of another group (Fig. 3B ) did produce elevated concentrations of ITT at this time after irradiation. Failure to consistently detect the increases in LH and ITT that had been observed previously (6, 22, 35) may be attributable to the fact that, in all the previous experiments, the rats were killed at 10 or more weeks after irradiation, whereas here they were killed at only 5 wk.
Treatment with the GnRH antagonist reduced the FSH, LH, and ITT concentrations to 15%, 14%, and 6% of the values observed in irradiated-only rats (Fig. 5, F , K, and P). These measurements were taken 2 wk after GnRH-antagonist treatment, which is considered to be the midpoint of the treatment time.
T, DHT, MENT, and R1881, and E2 administered by different means significantly reversed the GnRH-antagonistinduced suppression of FSH (Fig. 5, G-J) ; only with the lower dose of TP was this increase in FSH levels not significant. The LH levels remained suppressed and not significantly different from the GnRH-antagonist-only-treated irradiated rats in all the steroid treated groups. In the group receiving GnRHϩantagonistϩ5 cm DHT (Fig. 5L) , one rat had an exceptionally high LH value, resulting in a high variation in the LH levels. The T treatment, especially the higher doses, in- , and androsterone (E and J) levels per testis in unirradiated (unirr.) control rats, irradiated-only rats, and irradiated rats treated with GnRH antagonist (IrrϩGnRH ant) with or without T or DHT (in the same experimental rats as represented in Fig.  3) . Significance of the difference (Dunnett's test) from irradiated-only rats (for unirradiated rats and irradiated rats receiving GnRH antagonist and GnRHantagonistϩandrogen treatments): *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; or from GnRH-antagonist-alone-treated rats (for rats receiving additional hormone treatments): † †, P Ͻ 0.01. creased the ITT concentrations and total amounts per testis in GnRH-treated irradiated rats in all four groups (Fig. 5 , Q-T and V-Y). The ITT levels in rats treated with different androgens were not as high as those treated with T, but the androgen administered would be expected to exert the primary direct inhibitory effect.
Treatment with exogenous DHT did not seem to increase its intratesticular concentration in GnRH-antagonist-treated irradiated rats (Fig. 3H ), but it did show a trend toward increasing total DHT levels per testis (Fig. 4H) . Whereas DHT treatment (particularly the lower dose) significantly reduced the intratesticular concentrations of androstenedione, T, and androstanediol (Fig. 3, F , G, and I), it had little effect on their total amounts per testis (Fig. 4, F, G, and I) . These results provide only equivocal evidence that DHT may inhibit spermatogenic recovery by direct action on the testis. In contrast, DHT treatment increased the serum DHT levels in the GnRH-antagonist-treated rats by several orders of magnitude (Fig. 6) , suggesting that the serum levels of the androgens may contribute significantly to inhibition of spermatogenic recovery.
E2 drastically reduced ITT concentration and amounts per testis to levels below those in GnRH-antagonist-only-treated irradiated rats (Fig. 5, T and Y) . We propose that this suppression of T levels contributed to the maintenance of spermatogenic recovery by E2, even though it produced an elevation of FSH (Fig 5J) , which we presume to be inhibitory.
Weights of androgen-responsive organs
The weights of the accessory sex glands, bulbocavernosus muscle, and testis were used as measures of androgenicity of the different androgenic steroids. These androgenic responses were compared with the associated TDI, which is a measure of spermatogonial differentiation.
Depletion of germ cells by irradiation reduced the weight of the testis to 38% of the unirradiated control levels at 5 wk after irradiation (Fig. 7A) . Treatment with GnRH antagonist, for 2 wk, further reduced the testis weight, to 19% of the unirradiated control, because of the withdrawal of gonadotropin and androgen support. This decline most likely reflects reduction in Sertoli cell secretions and shrinkage of the , and ITT (P-Y) levels in unirradiated control rats, irradiated-only rats, and irradiated (5 Gy) rats treated during 3-7 wk after irradiation with GnRH antagonist with or without one of the androgens or E2. The rats were killed at 5 wk after irradiation for hormone analysis and at wk 13 after irradiation for the analysis of spermatogenic recovery. Significance of the difference (Dunnett's test) from irradiated-only rats (for unirradiated rats and irradiated rats receiving hormone treatments): *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; or from GnRH-antagonist-alone-treated rats (for rats receiving additional hormone treatments) (Dunnett's test): †, P Ͻ 0.5; † †, P Ͻ 0.01; † † †, P Ͻ 0.001. Significance of difference between GnRH-antagonistϩT-treated irradiated rats and irradiated rats receiving GnRH antagonist and comparable doses of other steroids (t test): §, P Ͻ 0.05; § §, P Ͻ 0.01; § § §, P Ͻ 0.001. Inj, Injection.
Sertoli and Leydig cells (36) and is not necessarily directly related to the subsequent spermatogonial recovery. Support for this was obtained by the observation that testis weights were increased during the androgen treatments (Fig. 7, B-D) , whereas the TDI was decreased (Fig. 5, B-D) . In contrast to the testis, the weights of seminal vesicle, ventral prostate, and bulbocavernosus muscle were not altered by irradiation. However, all were significantly reduced during treatment with GnRH antagonist (Fig. 7, E, I , and M).
T, administered in different modes, increased the testis weights to various degrees in GnRH-antagonist-treated irradiated rats (Fig. 7, B-D) . DHT, MENT, and R1881 increased testis weights to levels equal to or more than those produced by relative doses of T. All the androgens tested significantly increased the weights of seminal vesicle, prostate, and bulbocavernosus muscle in these GnRH-antagonist-treated irradiated rats (Fig. 7, F-H , J-L, and N-P). All three additional androgens had greater stimulatory effect than did T on testis weight, compared with accessory sex organ weights (figure not shown), with the differential effect being most significant for R1881 (compare Fig. 7, D with H and L) .
The weights of these androgen-responsive tissues were correlated with the TDIs obtained after the androgen treatments (Fig. 8) . As indicated by the arrows, a shift in the lines upward and to the right corresponds to less spermatogonial inhibition and greater androgenicity; whereas a shift downward and to the left corresponds to greater spermatogonial inhibition and less androgenicity. The responses for all androgens except R1881 overlapped or paralleled each other, which is consistent with the different androgens acting doseresponsively through the same pathway. None of the additional androgens used were better than T in maintaining the weights of the testis, seminal vesicle, ventral prostate, and muscle tissue, relative to their inhibition of GnRH-antagonist-stimulated spermatogenic recovery (Fig. 8) . In fact, MENT was the poorest of all, given that it inhibited spermatogonial differentiation at doses required for the maintenance of androgen-responsive tissue weights more than did T. Of all androgen treatments tested, T (given in the form of TP as daily injections) was the best in meeting the criterion of maximizing androgenicity and minimizing spermatogonial inhibition.
Discussion
We had previously demonstrated that exogenous T inhibited GnRH-analog-stimulated spermatogenic recovery in irradiated rats, at least by acting through the AR (7). That study led to the conclusion that the inhibitory factor must be T or an androgenic metabolite of T. Other studies showed that suppression of androgens, using GnRH analogs, also stimulated spermatogonial differentiation in rats after spermatogenesis had been inhibited by procarbazine (6), hexanedione (37), heat treatment (38) , or aging (39) . GnRH-antagonist treatment also stimulated spermatogonial differentiation in juvenile spermatogonial depletion (jsd) mutant mice, which are depleted of all germ cells except A spermatogonia (40, 41) . Further, this differentiation was also suppressed in jsd mice by exogenous T through an AR-dependent mechanism (41) . The similarities of these results indicate that T and the other androgens that were shown here to inhibit spermatogenesis after irradiation are also likely to be involved in the inhibition of spermatogenesis in these instances.
FIG. 6. Serum T (A) and DHT (B) levels in unirradiated control rats, irradiated-only rats, and irradiated rats (5 Gy) treated with GnRH antagonist with or without T or DHT. Rats were treated with hormones, starting at 3 wk after irradiation, and were killed at 5 wk after irradiation. Significance of the difference (Dunnett's test) from irradiated-only rats: ***, P Ͻ 0.001; or from GnRH-antagonist-alone-treated rats (for rats receiving additional hormone treatments): † † †, P Ͻ 0.001. Significance of the difference of the indicated group from irradiated-only rats as analyzed by Dunnett's test: a P Ͻ 0.001. Significance of the difference of the indicated group from GnRH-antagonist-alonetreated irradiated rats as analyzed by Dunnett's test:
b P Ͻ 0.001. Significance of difference between GnRH-antagonist ϩ T-treated irradiated rats and irradiated rats receiving GnRH antagonist and comparable doses of other androgens (Student's t test):
c P Ͻ 0.05 and
The present study demonstrates that the spermatogenic inhibitory property in irradiated rats is not limited to any particular androgen. Four androgens (T, R1881, DHT, and MENT), all having different metabolic properties, inhibited spermatogenic recovery. The relatively unchanged intratesticular concentrations of androgenic metabolites of T, androstanediol, androstenedione, DHT, and androsterone, after irradiation, rules out the possibility that the adverse effect of irradiation on spermatogenesis is caused by altered production of these androgens. Furthermore, the levels of these androgenic metabolites changed less after stimulation of spermatogonial differentiation with GnRH-antagonist treatment than did T, indicating that none of these metabolites had more potential to inhibit spermatogenic recovery than did T.
Although the previous study indicated that T was likely exerting its inhibitory effect directly on the testis (7), extratesticular sites of action could not be ruled out. The ITT levels in the GnRH-antagonist-treated rats, with or without additional doses of T, showed a fairly good inverse correlation with spermatogenic recovery as observed earlier (7) . Nevertheless, the significant suppression of spermatogenic recovery, which was not associated with significant increases in ITT and in testicular DHT concentrations, by a low dose of TP or DHT, respectively, suggest that the greatly increased serum levels of these androgens acting on an extratesticular target may contribute to the spermatogenic suppression. The androgens may act on the pituitary to alter serum gonadotropin levels to affect spermatogenesis. As observed earlier with T, the other androgens did not have any effect on LH levels; and furthermore, the serum LH levels did not correlate with spermatogenic recovery after irradiation (7). However, they did reverse the GnRH-antagonist-induced reduction of FSH levels in these rats, presumably by direct up-regulation of FSH␤-gene transcription in the pituitary (42) ; the resulting increase in FSH levels may contribute to the inhibition of spermatogonial differentiation.
When we compared the FSH levels with spermatogenic recovery in irradiated rats that received various androgens, a negative correlation was found between TDI and FSH (r ϭ 0.94) (Fig. 9) , which extends our earlier observations (7) . Only the GnRH-antagonist-treated irradiated rats that were given the higher doses of TP by injection showed a deviation in this regard. Thus, although this study was designed to test the inhibitory properties of the androgens, we also obtained additional evidence that the increases in FSH produced
FIG. 7. Weights (wt) of testis (A-D), seminal vesicle (ves.) (E-H), ventral prostate (I-L)
, and bulbocavernosus (Bulbo cav.) muscle (M-P) in unirradiated control rats, irradiated-only rats, and irradiated (5 Gy) rats treated with GnRH antagonist with or without one of the androgens. Rats were treated with hormones, starting at 3 wk after irradiation, and were killed at 5 wk. Significance of the difference from irradiated-only rats (for unirradiated rats and irradiated rats receiving hormone treatments) (Dunnett's test): **, P Ͻ 0.01; ***, P Ͻ 0.001. Significance of the difference of testis weights from irradiated GnRH-antagonist-alone-treated rats (for rats receiving additional hormone treatments) (Dunnett's test): †, P Ͻ 0.5; † †, P Ͻ 0.01; † † †, P Ͻ 0.001. The weights of seminal vesicle, prostate, and bulbocavernosus muscle were significantly higher (P Ͻ 0.001) in all the rats that received GnRH-antagonistϩandrogen, compared with GnRH-antagonist-only-treated irradiated rats; and hence, the symbols ( † † †) are not shown on the figure for these three sets of graphs. Significance of difference between GnRH-antagonistϩT-treated irradiated rats and irradiated rats receiving GnRH antagonist and comparable doses of other androgens (t test): §, P Ͻ 0.05; § §, P Ͻ 0.01.
by the androgen treatments may inhibit spermatogenic recovery.
We propose that, in addition to intratesticular action of androgen to inhibit spermatogonial differentiation, there is most likely an extratesticular site of action, which could be the regulation of FSH in the pituitary. This FSH could have a synergistic or additive effect, with intratesticular androgen levels, in inhibiting spermatogonial differentiation in irradiated rats. In contrast, FSH could not be implicated in the inhibition of spermatogonial differentiation in jsd mice; and hence, the mouse model differs, in that inhibition of spermatogonial differentiation seems to be attributable solely to the intratesticular action of androgen (41, 43) . We are currently testing whether FSH has a direct inhibitory effect on spermatogenic recovery in irradiated rats and are performing additional experiments to determine the relative roles of intratesticular vs. extratesticular sites of androgen action.
The suggestion that androgens and FSH have additive effects on inhibiting spermatogenesis in irradiated rats has precedence in the additive effects of these hormones in supporting spermatogenesis. In unirradiated rats with suppressed gonadotropin or T levels, exogenous T, DHT, and R1881 had similar effects in supporting the later steps of spermatogenesis. In these cases, FSH also supports the later stages of differentiation. In normal rats, spermatogonial survival and differentiation are qualitatively independent of T and FSH (44 -47) . The numbers of spermatogonia and spermatocytes produced can be modulated by, at most, a factor of two by FSH levels in both rodents (48) and primates (49) . The inhibition of the differentiation of A spermatogonia in irradiated rats by moderate levels of ITT and other androgens and/or serum FSH indicates that these hormones are acting, in an inhibitory manner, on a stage of spermatogenesis that is normally only weakly dependent on hormone stimulation. The molecular basis of the negative effects of these two hormones on spermatogenesis is, as yet, not known.
Similar to androgens, exogenous E2 also increased the FSH levels in GnRH-antagonist-treated irradiated rats but, unlike the situation with androgens E2, did not inhibit GnRHantagonist-stimulated spermatogenic recovery. Thus, the FSH Rats were killed during treatment at 5 wk after irradiation (for the analysis of tissue weights) or at 13 wk after irradiation (for histological analysis of tubule differentiation). TP was given by daily injection (Ⅺ-Ⅺ); T was given using osmotic pumps (E-E) or SILASTIC capsules (F-F). DHT was administered using SILASTIC capsules (‚-‚); MENT using osmotic pumps (छ-छ), and R1881 by daily injection (ƒ-ƒ). A common line is drawn through data points from rats receiving T by pumps and capsules. The arrow with a thick head (➝) represents the direction of a positive androgenic tissue response and less inhibition of TDI, and the arrow with a thin head (3) represents the direction of greater inhibition of tubule differentiation with less androgenic tissue response.
FIG. 9. Scatter plot of serum FSH levels during the treatment period (wk 5) vs. subsequent tubule differentiation (wk 13) in irradiated-only rats (filled hexagon), GnRH-antagonist-treated irradiated rats (open hexagon), and GnRH-antagonist-treated irradiated rats that received TP by daily injection (Ⅺ), T by osmotic pump or SILASTIC capsules (E), DHT (‚), MENT (छ), R1881 (ƒ), or E2 (OE). The fit was done using a sigmoid curve and includes all the points except the one for GnRHantagonistϩE2.
